|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 MediXall Group, Inc. 10-Q 9/30/22 47:2.8M Edgar Filing LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 628K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 17K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 17K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 14K
11: R1 Cover HTML 64K
12: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 103K
13: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 38K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Operations HTML 88K
(Unaudited)
15: R5 Consolidated Statements of Changes in HTML 80K
Stockholders' Equity (Deficit) (Unaudited)
16: R6 Consolidated Statements of Changes in HTML 17K
Stockholders' Equity (Deficit) (Unaudited)
(Parenthetical)
17: R7 Condensed Consolidated Statements of Cash Flows HTML 88K
(Unaudited)
18: R8 Organization and Nature of Operation HTML 20K
19: R9 Asset Acquisition HTML 19K
20: R10 Going Concern HTML 21K
21: R11 Summary of Significant Accounting Policies HTML 69K
22: R12 Right-to-use Intellectual Property HTML 30K
23: R13 Preferred Stock HTML 26K
24: R14 Related Party Transactions HTML 34K
25: R15 Senior Convertible Debentures and Warrants HTML 31K
26: R16 Summary of Significant Accounting Policies HTML 102K
(Policies)
27: R17 Summary of Significant Accounting Policies HTML 49K
(Tables)
28: R18 Right-to-use Intellectual Property (Tables) HTML 30K
29: R19 Related Party Transactions (Tables) HTML 26K
30: R20 Senior Convertible Debentures and Warrants HTML 25K
(Tables)
31: R21 Asset Acquisition (Details Narrative) HTML 22K
32: R22 Going Concern (Details Narrative) HTML 23K
33: R23 Summary of Significant Accounting Policies HTML 28K
(Schedule of Basic and Diluted EPS) (Details)
34: R24 Summary of Significant Accounting Policies HTML 22K
(Schedule of potentially dilutive securities)
(Details)
35: R25 Summary of Significant Accounting Policies HTML 18K
(Details Narrative)
36: R26 Right-to-use Intellectual Property (Schedule of HTML 22K
Right-to-use Intellectual Property) (Details)
37: R27 Right-to-use Intellectual Property (Schedule of HTML 30K
amortization expense for right-to-use intellectual
property) (Details)
38: R28 Preferred Stock (Details Narrative) HTML 37K
39: R29 Related Party Transactions (Details) HTML 32K
40: R30 Related Party Transactions (Details Narrative) HTML 29K
41: R31 Senior Convertible Debentures and Warrants HTML 30K
(Details)
42: R32 Senior Convertible Debentures and Warrants HTML 43K
(Details Narrative)
45: XML IDEA XML File -- Filing Summary XML 78K
43: XML XBRL Instance -- mdxl_10q_htm XML 646K
44: EXCEL IDEA Workbook of Financial Reports XLSX 71K
7: EX-101.CAL XBRL Calculations -- mdxl-20220930_cal XML 107K
8: EX-101.DEF XBRL Definitions -- mdxl-20220930_def XML 226K
9: EX-101.LAB XBRL Labels -- mdxl-20220930_lab XML 485K
10: EX-101.PRE XBRL Presentations -- mdxl-20220930_pre XML 398K
6: EX-101.SCH XBRL Schema -- mdxl-20220930 XSD 87K
46: JSON XBRL Instance as JSON Data -- MetaLinks 204± 287K
47: ZIP XBRL Zipped Folder -- 0001553350-22-000902-xbrl Zip 130K
Exhibit 31.1
CERTIFICATIONS
I, Travis Jackson, certify that:
1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2022 of MediXall Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the year covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Dated: November 14, 2022 | /s/ Travis Jackson |
| Travis Jackson | |
|
Chief Executive Officer (principal executive officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/14/22 | None on these Dates | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||